Advertisement Pharmaceutical Business review - Page 4544 of 5288 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 28, 2026

FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911

The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.

Continue
K-911 is being developed as a topical ophthalmic monotherapy formulated as a sterile solution. Credit: Gorodenkoff / Shutterstock.com.
August 27, 2026

FDA grants RPDD to ReviR’s RTX-117 for CMT

CMT consists of a group of inherited neuromuscular disorders, often presenting in childhood or adolescence. Credit: SkazovD/Shutterstock.com.
August 26, 2026

McKesson to acquire Precision Medicine Group for $2.25bn

Precision Medicine Group will operate within McKesson once the transaction receives final regulatory and closing approvals. Credit: Piotr Swat / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy
  2. Jazz secures FDA approval for Ziihera in advanced HER2+ GEA
  3. Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
  4. Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
  5. Johnson & Johnson’s multiple myeloma treatment secures EC approval

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography